Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy
Abstract Background We have evaluated the efficacy of targeting the toxic, oligomeric form of tau protein by passive immunotherapy in a mouse model of synucleinopathy. Parkinson’s disease and Lewy body dementia are two of the most common neurodegenerative disorders and are primarily characterized by...
Main Authors: | Julia E. Gerson, Kathleen M. Farmer, Natalie Henson, Diana L. Castillo-Carranza, Mariana Carretero Murillo, Urmi Sengupta, Alan Barrett, Rakez Kayed |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-03-01
|
Series: | Molecular Neurodegeneration |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13024-018-0245-9 |
Similar Items
-
TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia
by: Mauro Montalbano, et al.
Published: (2020-12-01) -
Subcellular localization of alpha-synuclein aggregates and their interaction with membranes
by: Fabiana Miraglia, et al.
Published: (2018-01-01) -
Formation and propagation of tau oligomeric seeds
by: Julia E. Gerson, et al.
Published: (2013-07-01) -
Tau oligomers: the toxic player at synapses in Alzheimer’s disease
by: Marcos Jair Guerrero-Munoz, et al.
Published: (2015-12-01) -
Editorial: Intracellular Mechanisms of α-Synuclein Processing
by: Friederike Zunke, et al.
Published: (2021-09-01)